Pipeline
ALX1
Water soluble, small molecule prodrug (<500 Da) that releases the pharmacologically active metabolite, Nitric Oxide (NO) with sustained release duration of up to 8 hours. This candidate is formulated as a buffered aqueous solution for oral inhalation via a customized PARI eFlow® nebulizer. The ALX1 pharmacology program includes in vitro and in vivo evidence of anti-inflammatory target engagement as well as antimicrobial efficacy against P. aeruginosa and Non-tuberculous mycobacterium infections.
Learn more about Nitric Oxide Prodrugs.